-
-
SHOP
PRODUCT CATEGORY
CONTACT US
ERG(C12A8),RMab
The approximate 50% of prostate cancers has fusion mutations, and TMPRSS2 ERG is the most common fusion gene. It is closely related to the aggressiveness and prognosis of prostate cancer. The EGR positive patients tend to have a higher stage of prostate cancer, a higher rate of recurrence, and a higher rate of pelvic lymph node metastasis.
Chat
message
Quote
Staining Tissue
[As Figure shows]
Esophagus tissue stained with ERG
[ Intended Use ]
The approximate 50% of prostate cancers has fusion mutations, and TMPRSS2 ERG is the most common fusion gene. It is closely related to the aggressiveness and prognosis of prostate cancer. The EGR positive patients tend to have a higher stage of prostate cancer, a higher rate of recurrence, and a higher rate of pelvic lymph node metastasis.
[Specifications ]
| Product Name | ERG(C12A8),RMab |
| Catalog No. | CER-0071 |
| Intended Use | IVD, RUO |
| Species Reactivity | Human; others not tested |
| Cellular Localization | Cytoplasm / Nucleus |
| Antibody Type | Rabbit Monoclonal |
| Clone | C12A8 |
| Format and Volume | Ready-to-use: 1mL, 3mL, 6mL Concentrated: 0.1mL, 0.2mL and 1mL |
[ Datasheets & SDS ]
| IVD Datasheet (IFU) | ↕️ Download |
| RUO Datasheet (IFU) | ↕️ Download |
| SDS sheet | check with sales |
[Storage and Validity]
Store at 2~8°C. Avoid freezing.
Maintain temperature below room temperature during transport, ensuring it does not exceed one week.
Related Product
